Confinement of unliganded EGFR by tetraspanin nanodomains gates EGFR ligand binding and signaling

Confinement of unliganded EGFR by tetraspanin nanodomains gates EGFR ligand binding and signaling

Abstract The epidermal growth factor receptor (EGFR) is a central regulator of cell physiology. EGFR is activated by ligand binding, triggering receptor dimerization, activation of kinase activity, and intracellular signaling. EGFR is transiently confined within various plasma membrane nanodomains,...

Full description

Bibliographic Details
Main Authors:	Michael G. Sugiyama, Aidan I. Brown, Jesus Vega-Lugo, Jazlyn P. Borges, Andrew M. Scott, Khuloud Jaqaman, Gregory D. Fairn, Costin N. Antonescu
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-05-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-023-38390-z

Similar Items

Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers
by: R. Sumanth Iyer, et al.
Published: (2024-03-01)

The EGFR ligands Spitz and Keren act cooperatively in the Drosophila eye.
by: Brown, K, et al.
Published: (2007)

Microglial-stimulation of glioma invasion involves the EGFR ligand amphiregulin.
by: Salvatore J Coniglio, et al.
Published: (2021-01-01)

Quantification of ligand and mutation-induced bias in EGFR phosphorylation in direct response to ligand binding
by: Daniel Wirth, et al.
Published: (2023-11-01)

Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy
by: Zhulin Wang, et al.
Published: (2024-03-01)

mGluR5 is transiently confined in perisynaptic nanodomains to shape synaptic function
by: Nicky Scheefhals, et al.
Published: (2023-01-01)

Ectodomain shedding of EGFR ligands serves as an activation readout for TRP channels.
by: Manae Tatsumi, et al.
Published: (2023-01-01)

Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity
by: Sei-Yong Jun, et al.
Published: (2022-12-01)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
by: Jia-Shiuan Ju, et al.
Published: (2023-11-01)

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
by: Takahiro Yoshizawa, et al.
Published: (2021-04-01)

The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
by: Yosuke Kagawa, MD, et al.
Published: (2023-03-01)

Numerical computation of signal stimulation from Ligand-EGFR binding during invadopodia formation
by: Yaacob, Noorehan, et al.
Published: (2019)

EGFR amplification indicated poor prognosis in EGFR‐mutated lung cancer with leptomeningeal metastases
by: Di Geng, et al.
Published: (2024-02-01)

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors
by: Ikei S. Kobayashi, MD, PhD, et al.
Published: (2024-01-01)

Imaging cAMP nanodomains in the heart
by: Chao, Y, et al.
Published: (2019)

Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations
by: Yutaka Yamada, et al.
Published: (2021-09-01)

EGFR Mutation in Nasopharyngeal Carcinoma
by: Evren Uzun, et al.
Published: (2022-10-01)

Role of EGFR in the Nervous System
by: Roberta Romano, et al.
Published: (2020-08-01)

EGFR Signaling in Lung Fibrosis
by: Fabian Schramm, et al.
Published: (2022-03-01)

EGFR-Targeted Photodynamic Therapy
by: Luca Ulfo, et al.
Published: (2022-01-01)

ADAM17-mediated EGFR ligand shedding directs macrophage-promoted cancer cell invasion
by: Sebastian P. Gnosa, et al.
Published: (2022-09-01)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> Mutations
by: Kenichi Suda, et al.
Published: (2021-06-01)

Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer
by: Brian J. Thomas, et al.
Published: (2023-12-01)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
by: Xingyuan Li, et al.
Published: (2023-10-01)

Phosphorylated STYK1 restrains the inhibitory role of EGFR in autophagy initiation and EGFR-TKIs sensitivity
by: Cefan Zhou, et al.
Published: (2022-08-01)

PRMT1, a Key Modulator of Unliganded Progesterone Receptor Signaling in Breast Cancer
by: Lucie Malbeteau, et al.
Published: (2022-08-01)

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
by: Azhar Ali, et al.
Published: (2018-03-01)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
by: Keigo Kobayashi
Published: (2023-12-01)

Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study
by: Duangjai Todsaporn, et al.
Published: (2023-03-01)

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors
by: Felix Oh, et al.
Published: (2020-06-01)

Single-Molecule Super-Resolution Microscopy Reveals Heteromeric Complexes of MET and EGFR upon Ligand Activation
by: Marie-Lena I.E. Harwardt, et al.
Published: (2020-04-01)

Significance of programmed death‐ligand 1 expression in resected lung cancer and its relationship with EGFR mutation
by: Atsushi Osoegawa, et al.
Published: (2023-08-01)

Compositional nanodomain formation in hybrid formate perovskites
by: Donlan, E, et al.
Published: (2017)

Dynamic label-free imaging of lipid nanodomains
by: de Wit, G, et al.
Published: (2015)

EGFR signaling networks in cancer therapy /
by: Haley, John D
Published: (2008)

EGFR inhibitors in the treatment of colorectal cancer
by: M. В. Zabelin, et al.
Published: (2018-09-01)

Structure of unliganded membrane-proximal domains FN4-FN5-FN6 of DCC
by: Lorenzo I. Finci, et al.
Published: (2017-06-01)

Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations
by: Wuwu Ding, et al.
Published: (2024-01-01)

Correlation of MRI quantitative perfusion parameters with EGFR, VEGF and EGFR gene mutations in non-small cell cancer
by: Mingyue Zou, et al.
Published: (2024-02-01)

EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer
by: Carolin Selenz, et al.
Published: (2022-08-01)